347 related articles for article (PubMed ID: 32603772)
41. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
Chrousos GP; Meduri GU
Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
[No Abstract] [Full Text] [Related]
42. Drug repurposing and cytokine management in response to COVID-19: A review.
Heimfarth L; Serafini MR; Martins-Filho PR; Quintans JSS; Quintans-Júnior LJ
Int Immunopharmacol; 2020 Nov; 88():106947. PubMed ID: 32919216
[TBL] [Abstract][Full Text] [Related]
43. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
Front Immunol; 2020; 11():1648. PubMed ID: 32754159
[TBL] [Abstract][Full Text] [Related]
44. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs.
Tufan A; Avanoğlu Güler A; Matucci-Cerinic M
Turk J Med Sci; 2020 Apr; 50(SI-1):620-632. PubMed ID: 32299202
[TBL] [Abstract][Full Text] [Related]
45. Sofosbuvir for COVID-19 infection: A potential candidate.
Gupta R; Dhamija P
Indian J Pharmacol; 2020; 52(3):232-233. PubMed ID: 32874010
[No Abstract] [Full Text] [Related]
46. A hypothesis on the role of the human immune system in covid-19.
Khashkhosha HK; Elhadi M
Med Hypotheses; 2020 Oct; 143():110066. PubMed ID: 32629204
[TBL] [Abstract][Full Text] [Related]
47. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
Saul S; Einav S
ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
[TBL] [Abstract][Full Text] [Related]
48. Purposing Saikosaponins for the treatment of COVID-19.
Bahbah EI; Negida A; Nabet MS
Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
[No Abstract] [Full Text] [Related]
49. [Not Available].
Balavoine JF
Rev Med Suisse; 2020 May; 16(695):1126. PubMed ID: 32462848
[No Abstract] [Full Text] [Related]
50. Cytokine storm in COVID-19 and parthenolide: Preclinical evidence.
Bahrami M; Kamalinejad M; Latifi SA; Seif F; Dadmehr M
Phytother Res; 2020 Oct; 34(10):2429-2430. PubMed ID: 32472655
[TBL] [Abstract][Full Text] [Related]
51. Leukotrienes, a potential target for Covid-19.
Citron F; Perelli L; Deem AK; Genovese G; Viale A
Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
[No Abstract] [Full Text] [Related]
52. Statins in coronavirus outbreak: It's time for experimental and clinical studies.
Bifulco M; Gazzerro P
Pharmacol Res; 2020 Jun; 156():104803. PubMed ID: 32289478
[No Abstract] [Full Text] [Related]
53. Is the type of diabetes treatment relevant to outcome of COVID-19?
Bloomgarden Z
J Diabetes; 2020 Jul; 12(7):486-487. PubMed ID: 32353193
[No Abstract] [Full Text] [Related]
54. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.
Georgiev T
Rheumatol Int; 2020 May; 40(5):825-826. PubMed ID: 32232552
[No Abstract] [Full Text] [Related]
55. Silencing of immune activation with methotrexate in patients with COVID-19.
Safavi F; Nath A
J Neurol Sci; 2020 Aug; 415():116942. PubMed ID: 32471659
[No Abstract] [Full Text] [Related]
56. Why not consider an endothelin receptor antagonist against SARS-CoV-2?
Javor S; Salsano A
Med Hypotheses; 2020 Aug; 141():109792. PubMed ID: 32361169
[No Abstract] [Full Text] [Related]
57. Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial.
Kaddam L; Babiker R; Ali S; Satti S; Ali N; Elamin M; Mukhtar M; Elnimeiri M; Saeed A
Trials; 2020 Sep; 21(1):766. PubMed ID: 32891160
[TBL] [Abstract][Full Text] [Related]
58. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
59. As a potential treatment of COVID-19: Montelukast.
Fidan C; Aydoğdu A
Med Hypotheses; 2020 Sep; 142():109828. PubMed ID: 32416408
[TBL] [Abstract][Full Text] [Related]
60. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Zhang W; Zhao Y; Zhang F; Wang Q; Li T; Liu Z; Wang J; Qin Y; Zhang X; Yan X; Zeng X; Zhang S
Clin Immunol; 2020 May; 214():108393. PubMed ID: 32222466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
